Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro

British Journal of Cancer

Volumn 74, Issue 5, 1996, Pages 704-710

  Kano, Y ^a   Akutsu, M ^a   Tsunoda, S ^a   Ando, J ^a   Matsui, J ^a   Suzuki, K ^a   Ikeda, T ^b   Inoue, Y ^b   Adachi, K I ^c  

^a TOCHIGI CANCER CENTER   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c NIPPON KAYAKU CO LTD   (Japan)

Author keywords

5 fluorouracil; Drug combination; Paclitaxel

Indexed keywords

FLUOROURACIL; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0029738931     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.425     Document Type: Article

References (31)

1. ARBUCK SG. (1994). Paclitaxel: what schedule? Whal dose? J. Clin. Oncol., 12, 233 236.
2. ASHELE C, SOBRERO A. AND FADERAN MA. (1992). Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res., 52, 1855-1864.
3. DONEHOWER RC, ROWINSKY EK AND GROCHOW LB. (1987). Phase I trial of taxol in patients with advanced cancer. Cancer Treat. Rep., 71, 1171 1177.
4. DONEHOWER RC AND ROWINSKY EK. (1993). An overview of experience with taxol (paclitaxel) in the U.S.A. Cancer Treat. Rev., 19, (Suppl. C), 63 78.
5. ELKORDY M, MATTERS L, CONIGLIO D, PETROS W, VREDEN-BURGH J, HUSSEIN A, MEISENBERG B, RUBIN P, ROSS M AND PETERS W. (1994). The effect of continuous infusion 5-FU with or without taxol as induction therapy in stage IV breast carcinoma (abstract). Proc. Am. Soc. Clin. Oncol., 13, 95.
6. ETTINGER DS, FINKELSTEIN DM, SARMA R AND JOHNSON, DH. (1993). Phase II study of taxol in patients with extensive-stage small cell lung cancer: an Eastern Cooperative Oncology Group study (abstract). Proc. Am. Soc. Clin. Oncol., 12, 329.
7. GREM JL, TUTSCH KD AND SIMON KJ. (1987). Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat. Rep., 71, 1179 1184.
8. GUPTA RS. (1985). Cross-resistance of vinblastine- and taxol-resistant mutants of chinese hamster ovary cells to other anticancer drugs. Cancer Treat. Rep., 69, 515 521.
9. HOLMES FA, WALTERS RS, THERIAULT RL, FOMAN AD, NEWTON LK, RABER MN, BUZDAR AU, FRYE DK AND HORTOBAGYI GN. (1991). Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl Cancer Inst., 83, 1797 1805.
10. HOLMES FA, NEWMANN RA, MADDEN T, VALERO V, FRASCHINI G, WALTERS S, BOOSTER DJ, BUZDAR AU, WIKKY J AND HORTOBAGYI GN. (1994). Schedule dependent pharmacokinetics (PK) in a phase I trial of taxol and doxorubicin as initial chemotherapy for metastatic breast cancer. 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy. 197.
11. KANO Y, OHNUMA T, OKANO T AND HOLLAND JF. (1988). Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res., 48, 351 356.
12. KANO Y, SAKAMOTO S, KASAHARA T, AKUTSU M, INOUE Y AND MIURA Y. (1991). In vitro effects of amsacrine in combination with other anticancer agents. Leukemia Res., 15, 1059 1066.
13. KANO Y, SUZUKI K, AKUTSU, M, SUDA K, INOUE Y, YOSHIDA M, SAKAMOTO S, AND MIURA Y. (1992). Effects of CPT-11 in combination with other anticancer agents in culture. Int. J. Cancer, 50, 604 610.
14. KLAASSEN U, WILKE HC, PHILIPPUU PARIC, STRUMBERG D, HARSTRICK A, EBERHARD W, DJERGARTEN K, LENAZ L AND SEEBER S. (1995). Phase I/II study with paclitaxel in combination with weekly high dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer (abstract). Proc. Am. Soc. Clin. Oncol., 14, 122.
15. KUMAR N. (1981). Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem., 256, 10435 10441.
16. LAI GM, CHEN YN, MICKLEY LA, FOJO AT AND BATES SE. (1991). P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int. J. Cancer, 49, 696-703.
17. LOPES NM, ADAMS EG, PITTS TW AND BHUYAN BK. (1993). Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol., 32, 235 242.
18. McGUIRE WP, ROWINSKY EK, ROSENSHEIN NB, GRUMBINE FC, ETTINGER DS, ARMSTRONG DK AND DONEHOWER RC. (1989). Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111, 273-279.
19. MADAJEWICZ S, LIPERA W, PENDYALA L, HENTSCHEL P, AVVENTO L, CHOWHAN N AND OSTRO S. (1995). Phase I study of 96 hour continuous intravenous infusion of taxol followed by 24 hours Cl of 5-fluorouracil and folonic acid (abstract). Proc. Am. Soc. Clin. Oncol., 14, 489.
20. MOSMANN T. (1983). Rapid colormetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods, 65, 55 63.
21. MURPHY WK, FOSSELLA FV, WINN RJ, SHIN DM, HYNES E, GROSS HM, ENRIQUE D, LEIMERT J, DHINGRA H, RABER MN, KRAKOFF IH AND HONG WK. (1933). Phase II study of taxol in untreated advanced non-small cell lung cancer. J. Natl Cancer Inst., 85, 384-387.
22. PAUL DM, GARETT AM, MESHAD M, DEVORE RD, PORTER LL AND JOHNSON DH. A phase II trial of paclitaxel, 5-fluorouracil & leucovorin in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 14, 140.
23. ROWINSKY EK, DONEHOWER RC, JONES RJ AND TUCKER RW. (1988). Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res., 48, 4093 4100.
24. ROWINSKY EK, GILBERT MR, McGUIRE WP, NOE DA, GROCHOW LB, FARASTIERE AA, ETTINGER DS, LUBEIKA BG, CLARK B, SARTORIUS SE, CORNBLTH DR, HENDRICKS CB AND DONEHOWER RC. (1991). Sequence of taxol and eisplatin: a phase I and pharmacologic study. J. Clin. Oncol., 9, 1692 1703.
25. SCHIFF PB, FANT J AND HORWITZ SB. (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665 667.
26. SCHIFF PB AND HORWITZ SB. (1981). Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule- associated proteins. Biochemistry. 20, 3247 3252.
27. STEEL GG AND PECKHAM MJ. (1979). Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys., 5, 85 93.
28. TAKIMOTO CH, MORRISON GB, FRAME JN, LIANG MD, NAKASHIMA H, LIEBERMAN R, HAMILTON JM, ALLEGRA CJ AND GREM JL. A phase I and pharmacologic trial of paclitaxel and 5-fluorouracil plus leucovorin in patients with solid tumours. Proc. Am. Soc. Clin. Oncol., 14, 471.
29. WANI MC, TAYLOR HL, WALL ME, COOGEN P AND MCPHAIL AT. (1971). Plant untitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agents from taxus brevifolia. Am. Chem. Soc., 93, 2325-2327.
30. WIERNIK PH, SCHWARTZ EL, STRAUMANN JJ, LIPTON RB, DUTCH JP AND EIZIG JJ. (1987). Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol., 5, 1232 1239.
31. WILSON WH, BERG SL, BRYANT G, WITTES RE, BATES S, FOJO A, STEINBERG SM, GOLDSPIEL BR, HERDT J, O'SHAUGHNESSY J, BALIS FM AND CHABNER BA. (1994). Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trail of 96-hour infusion. J. Clin. Oncol., 12, 1621 1629.